410P Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study

G Liposits,H Skuladottir,S Möller,P Pfeiffer,B Glimelius,J Ryg,H Sorbye,C-H Shah,P.J Osterlund,E Hofsli,C Qvortrup,L Poulsen Oestergaard,A Berglund,S.B Winther

doi:10.1016/j.annonc.2022.07.548

410P Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study

G Liposits, H Skuladottir + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.548

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Regionshospitalet Herning, University of Southern Denmark, Odense University Hospital, Uppsala University Hospital, Haukeland University Hospital, Karolinska University Hospital, Karolinska Institutet, Tampere University Hospital, Tampere University, St Olav's University Hospital, Copenhagen University Hospital, Aalborg University Hospital

#Geriatric Screening Tools #Colorectal Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Appropriate patient selection based on functional status is crucial when considering older adults for palliative chemotherapy. This pre-planned analysis of the randomized NORDIC9-study explores the prognostic value of four functional status measures regarding progression-free survival (PFS) and overall survival (OS) in vulnerable older patients with metastatic colorectal cancer (mCRC) receiving palliative chemotherapy.

Full Text